This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wagner, J. D. Articles by Hayes, J. T. Search for Related Content PubMed PubMed Citation Articles by Wagner, J. D. Articles by Hayes, J. T. Social Bookmarking                            What's this?

Prospective Study of Fluorodeoxyglucose–Positron Emission Tomography Imaging of Lymph Node Basins in Melanoma Patients Undergoing Sentinel Node Biopsy

From the Departments of Surgery, Radiology, Pathology, Medicine, and Biostatistics, Indiana University School of Medicine, Indiana University–Purdue University at Indianapolis, Indianapolis, IN.

Address reprint requests to Jeffrey D. Wagner, MD, RT 471, Cancer Pavilion Building, 535 Barnhill Dr, Indianapolis, IN 46202.

PURPOSE: To prospectively compare positron emission tomography (PET) imaging of regional lymph node basins to sentinel node biopsy (SNB) in patients with American Joint Committee on Cancer (AJCC) stage I, II, and III melanoma localized to the skin.

METHODS: Patients with cutaneous melanoma with Breslow's depth greater than 1 mm (AJCC T2-4N0M0) or localized regional cutaneous recurrence (TxN2bM0) underwent whole-body imaging of glucose metabolism with fluorodeoxyglucose (FDG) PET followed by SNB. PET scans were interpreted in a blinded fashion and compared with histologic analyses of SNB specimens and clinical follow-up examination. Nodal tumor volumes were estimated.

RESULTS: Eighty-nine lymph node basins were evaluated by FDG-PET and SNB in 70 assessable patients. Eighteen patients (25.7%) had lymph node metastases at the time of FDG-PET imaging: 17 proved by SNB (24.3%) and one by follow-up examination (1.4%). Median tumor volume in positive sentinel node basins was 4.3 mm³ (range, 0.07 to 523 mm³). Sensitivity of SNB for detection of occult regional lymph node metastases was 94.4%, specificity was 100%, positive predictive value (PPV) was 100%, and negative predictive value (NPV) was 98.6%. Sensitivity of FDG-PET was 16.7%, specificity was 95.8%, PPV was 50%, and NPV was 81.9%. At a median follow-up duration of 16.6 months, seven patients (10%) developed recurrent disease. PET predicted one recurrence (14.3%) in a node basin missed by SNB.

CONCLUSION: FDG-PET is an insensitive indicator of occult regional lymph node metastases in patients with melanoma because of the minute tumor volumes in this population. FDG-PET does not have a primary role for staging regional nodes in patients with clinically localized melanoma.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J W CRAWSHAW, P HADWAY, D HOFFLAND, S BASSINGHAM, C M CORBISHLEY, Y SMITH, J PILCHER, R ALLAN, N A WATKIN (Urol), and S D HEENAN Sentinel lymph node biopsy using dynamic lymphoscintigraphy combined with ultrasound-guided fine needle aspiration in penile carcinoma Br. J. Radiol., January 1, 2009; 82(973): 41 - 48. [Abstract] [Full Text] [PDF]

				B. Krug, R. Crott, M. Lonneux, J.-F. Baurain, A.-S. Pirson, and T. Vander Borght Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic Review Radiology, December 1, 2008; 249(3): 836 - 844. [Abstract] [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, J. J. Erasmus, M. T. Truong, H. Macapinlac, M. I. Ross, and J. E. Gershenwald Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. Am. J. Roentgenol., July 1, 2006; 187(1): W117 - W119. [Full Text] [PDF]

				T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma J. Nucl. Med., June 1, 2006; 47(6): 957 - 967. [Abstract] [Full Text] [PDF]

				M. S. Brady, T. Akhurst, K. Spanknebel, S. Hilton, M. Gonen, A. Patel, and S. Larson Utility of Preoperative [(18)]F Fluorodeoxyglucose-Positron Emission Tomography Scanning in High-Risk Melanoma Patients Ann. Surg. Oncol., April 1, 2006; 13(4): 525 - 532. [Abstract] [Full Text] [PDF]

				M. J. Reinhardt, A. Y. Joe, U. Jaeger, A. Huber, A. Matthies, J. Bucerius, R. Roedel, H. Strunk, T. Bieber, H.-J. Biersack, et al. Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients J. Clin. Oncol., March 1, 2006; 24(7): 1178 - 1187. [Abstract] [Full Text] [PDF]

				P. B. Clark, V. Soo, J. Kraas, P. Shen, and E. A. Levine Futility of fluorodeoxyglucose f 18 positron emission tomography in initial evaluation of patients with t2 to t4 melanoma. Arch Surg, March 1, 2006; 141(3): 284 - 288. [Abstract] [Full Text] [PDF]

				R. Patzwahl, K. Landau, and S. S. Kollias Atypical Midface Tumor Complicating Nevus of Ota AJNR Am. J. Neuroradiol., September 1, 2005; 26(8): 2117 - 2121. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				D. Fuster, S. Chiang, G. Johnson, L. M. Schuchter, H. Zhuang, and A. Alavi Is 18F-FDG PET More Accurate Than Standard Diagnostic Procedures in the Detection of Suspected Recurrent Melanoma? J. Nucl. Med., August 1, 2004; 45(8): 1323 - 1327. [Abstract] [Full Text] [PDF]

				S. E. Finkelstein, J. A. Carrasquillo, J. M. Hoffman, B. Galen, P. Choyke, D. E. White, S. A. Rosenberg, and R. M. Sherry A Prospective Analysis of Positron Emission Tomography and Conventional Imaging for Detection of Stage IV Metastatic Melanoma in Patients Undergoing Metastasectomy Ann. Surg. Oncol., August 1, 2004; 11(8): 731 - 738. [Abstract] [Full Text] [PDF]

				J. D. Wagner Editorial: A Role for FDG-PET in the Surgical Management of Stage IV Melanoma Ann. Surg. Oncol., August 1, 2004; 11(8): 721 - 722. [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				J. D. Wagner, D. Z. Evdokimow, E. Weisberger, D. Moore, T.-Y. Chuang, S. Wenck, and J. J. Coleman III Sentinel Node Biopsy for High-Risk Nonmelanoma Cutaneous Malignancy Arch Dermatol, January 1, 2004; 140(1): 75 - 79. [Abstract] [Full Text] [PDF]

				D. C.P. Cobben, P. L. Jager, P. H. Elsinga, B. Maas, A. J.H. Suurmeijer, and H. J. Hoekstra 3'-18F-Fluoro-3'-Deoxy-L-Thymidine: A New Tracer for Staging Metastatic Melanoma? J. Nucl. Med., December 1, 2003; 44(12): 1927 - 1932. [Abstract] [Full Text] [PDF]

				S. W. Fosko, W. Hu, T. F. Cook, and V. J. Lowe Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck Arch Dermatol, September 1, 2003; 139(9): 1141 - 1146. [Abstract] [Full Text] [PDF]

				L. M. Jost ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma Ann. Onc., July 1, 2003; 14(7): 1012 - 1013. [Full Text] [PDF]

				G S Mijnhout, O S Hoekstra, A van Lingen, P J van Diest, H J Ader, A A Lammertsma, R Pijpers, S Meijer, and G J J Teule How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma J. Clin. Pathol., April 1, 2003; 56(4): 283 - 286. [Abstract] [Full Text] [PDF]

				L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]

				S. M. Swetter, L. A. Carroll, D. L. Johnson, and G. M. Segall Positron Emission Tomography Is Superior to Computed Tomography for Metastatic Detection in Melanoma Patients Ann. Surg. Oncol., August 1, 2002; 9(7): 646 - 653. [Abstract] [Full Text] [PDF]

				T. Belhocine, G. Pierard, M. de Labrassinne, T. Lahaye, and P. Rigo Staging of Regional Nodes in AJCC Stage I and II Melanoma: 18FDG PET Imaging versus Sentinel Node Detection Oncologist, August 1, 2002; 7(4): 271 - 278. [Abstract] [Full Text] [PDF]

				S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]

				R Allan Sentinel node localization: do or dye alone? Br. J. Radiol., June 1, 2001; 74(882): 475 - 477. [Full Text] [PDF]

				K.M. Acland, C. Healy, E. Calonje, M. O'Doherty, T. Nunan, C. Page, E. Higgins, and R. Russell-Jones Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant Melanoma J. Clin. Oncol., May 15, 2001; 19(10): 2674 - 2678. [Abstract] [Full Text] [PDF]

				G J R Cook The clinical use of PET--where are we now? Br. J. Radiol., May 1, 2001; 74(881): 399 - 401. [Full Text] [PDF]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]